GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
The user is experiencing chest sensitivity and muscle ache after using topical finasteride for a month and is concerned about potential gynecomastia. They are considering asking their doctor for blood work to check estrogen levels and are questioning whether to stop using finasteride.
A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.
The conversation discusses hair loss treatments, specifically mentioning Spiro, Min, Fin, and RU. It highlights that Spiro is generally for women and can affect men's hormonal balance.
User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.
The conversation discusses the potential of Sanguisorba Officinalis Root Extract as a treatment for hair loss by inhibiting FGF-5. The user also mentions the product évolis, which is based on this extract but is only available in the US and Australia.
N-Acetyl-Cysteine (NAC) is being explored for treating hair loss, but users report mixed results. Some also mention using Quercetin and Resveratrol without significant hair improvement.
GHK-Cu is being discussed as a potential treatment for male pattern baldness. Users are sharing experiences and asking about its effectiveness and side effects.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.
The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.
Bovine colostrum is being discussed for its potential in hair regeneration, with some users noting that oral consumption may not be effective due to stomach acid destroying exosomes. The conversation also touches on ethical concerns about sourcing colostrum.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
The user is experiencing hair shedding despite starting finasteride 4 months ago, with no signs of miniaturization. They are seeking advice after normal blood tests and similar family experiences.
User experienced hair thinning due to high cortisol and thyroid issues, along with insulin resistance. They are taking magnesium, zinc, vitamin D, calcium, and selenium as supplements.
An 18-year-old is seeking advice on microneedling while using RU58841 for hair loss. Recommendations include using a derma pen with 0.5mm needles every two weeks and avoiding RU application for 24 hours post-microneedling to prevent absorption into the bloodstream.
A user's successful hair transplant, with some people questioning the donor area regrowth, and others speculating that hair fibre may have been used to help fill in areas.
The conversation is about making a 20mg/ml RU58841 solution for hair loss treatment using ethanol and propylene glycol. The user receives advice on calculating the correct amount of RU58841 powder needed.
A 29-year-old male on 1 mg Finasteride for 3 months has experienced a significant increase in testosterone and estradiol levels, with no major side effects except slightly oilier skin and increased emotional sensitivity. The user is concerned about these hormonal changes and seeks advice, as their general practitioner is not knowledgeable about the issue.
Soy consumption may help prevent androgenic alopecia, but it can decrease sexual drive in some men. There is a connection between soy and androgenic alopecia, suggesting a potential protective effect.
The user seeks alternatives to Propylene Glycol (PG) for delivering topical finasteride due to scalp irritation. They consider using Propanediol 1,3 and ask for other suggestions.
The user had lab work done to check for thyroid issues and other factors related to hair loss. They are seeking advice on which lab results are important for understanding hair loss and what the optimal levels should be.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
A user is concerned about hair loss and acne from a one-week course of 70 mg/day oral prednisolone for severe tinnitus. They are asking if these side effects are common.
A user is concerned about taking 1mg/day of finasteride due to potential gynecomastia, given their blood results. They seek advice on how their hormone levels might be affected by blocking DHT.
The user experienced microinflammation on the crown after using mometasone furoate (Nasonex) nasal spray. They are seeking information on the relationship between this corticosteroid and hair loss.
RU58841 caused chest tightness, throat irritation, and headaches, leading the user to stop its use. The user plans to restart with a lower dose if symptoms fully disappear but remains cautious due to anxiety and side effects.
A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.